BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares of 5.91 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares · last filed 2023-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2022 was 5.91M shares, a 1.22% increase from fiscal 2021.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2021 was 5.84M shares, a 28.48% increase from fiscal 2020.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2020 was 4.54M shares, a 62.60% increase from fiscal 2019.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2019 was 2.79M shares, a 35.30% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 12 month |
|---|---|
| 2022-12-31 | 5.91M shares 10-K · filed 2023-02-27 |
| 2021-12-31 | 5.84M shares 10-K · filed 2022-02-28 |
| 2020-12-31 | 4.54M shares 10-K · filed 2021-03-01 |
| 2019-12-31 | 2.79M shares 10-K · filed 2020-03-13 |
| 2018-12-31 | 2.06M shares 10-K · filed 2019-03-14 |
| 2017-12-31 | 1.92M shares 10-K · filed 2018-03-12 |
| 2016-12-31 | 1.28M shares 10-K · filed 2017-02-27 |
| 2015-12-31 | 1.71M shares 10-K · filed 2016-02-26 |
| 2013-12-31 | 1.79M shares 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |